Diagnostic and prognostic implications of serum miR-101 in osteosarcoma

作者：Zhihong Yao, Cheng-han Li, Daoming Liang, Xiaotao Jiang, Jianwei Tang, Linhu Ye, Kai Yuan, Huimin Ren, Zhenxing Yang, Daxiang Jin, Shiyu Zhang, J.-Y. Ding, Ying Tang, Jing Xu, Kongning Chen, Weixing Xie, Dan‐qing Guo, J Cui · 发表于：Cancer Biomarkers · 年份：2018 · DOI：10.3233/cbm-171103 · 被引用次数：37 · 研究领域：MicroRNA in disease regulation、Circular RNAs in diseases、Cancer-related molecular mechanisms research

Blood-circulating microRNAs (miRNAs) have been reported to be used as potential biomarkers in various cancers. MiR-101 has been found to act as a tumor suppressor in many tumor types, but little is known for osteosarcoma. The purpose of this study was to investigate miR-101 expression in osteosarcoma patients and assess its correlation with clinical features and prognosis. Serum samples from 152 osteosarcoma patients and 70 healthy controls were detected using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The data showed that miR-101 expression levels were remarkably underexpressed in serum samples from osteosarcoma patients compared to controls, and the post-treatment serum miR-101 expression was significantly higher than that in the pre-treatment expression. Low serum miR-101 expression was positively associated with advanced clinical stage and distant metastasis. Receiver operating characteristic (ROC) curve analysis showed that serum miR-101 could serve as a useful marker for osteosarcoma diagnosis, with a high sensitivity and specificity. Moreover, patients with high miR-101 expression had longer overall survival and recurrence free survival than those with low miR-101 expression. In addition, both univariate and multivariate analyses showed that serum miR-101 downregulation was associated with shorter overall survival and recurrence free survival. Our present results implicated serum miR-101 might be a useful biomarker for the clinical diagnosi...